RAM-ACTIVE-INVESTMENTS
RAM Active Investments SA ("RAM AI"), a systematic asset manager based in Geneva, is launching a fund with the objective to tackle the climate emergency and to provide investors an active strategy with strong ESG standards. RAM AI’s innovative ESG approach is the result of extensive research exploring alternative data thanks to the successful development of the RAM AI Machine Learning (ML) infrastructure.
As the Climate Change emergency continues to grow RAM AI believes its role as an asset manager is to provide investors with a differentiated solution to low-carbon investing. Emmanuel Hauptmann who heads the Systematic Equity research shares: “The RAM ML team has made tremendous advances in building the strategy with the objective to provide a selection of best-in-class, low-carbon companies without compromising performance. ”
While many managers opt for a unidimensional approach to climate change within portfolios by reducing the weight of the worst polluters, RAM AI’s sustainable alpha approach aims to leverage a myriad of ESG and non-ESG data sources to identify the most attractive sustainable return opportunities in each industry. Nicolas Jamet, who leads the research efforts on ESG integration adds: “Our research effort is based on hypothesis testing; understanding how the ESG profile of a given company impacts, not only future stock performance, but also current/future fundamentals and ultimately financial returns.”
Thanks to a robust Machine Learning infrastructure, RAM AI applies a systematic process to select companies combining financial and ESG data, with both structured and unstructured (i.e. news-flow) inputs. To learn more about how AI is used to integrate unstructured ESG news-flow on companies to improve selection, please read our latest publication on the topic: A Natural Language Processing (NLP) based framework for ESG Integration .
RAM AI is excited about this development and sees it as a cornerstone to its commitment and long-term alignment towards the SDGs. The cross-fertilisation of ideas within the RAM research team will lead to more innovation across products using ESG data and NLP techniques to improve the alpha prediction.
The Fund is available in a UCITS format as of the 9th of July 2020 to investors in Luxembourg, Germany, Denmark, Spain, Netherlands, Italy, Norway, Sweden, Portugal, United Kingdom, Singapore and Japan. The fund is currently in the process of being registered in Switzerland. RAM AI will also aim to offset the Fund’s (low) carbon emissions (Scopes I and II) using carbon compensation certificates (CERs) in accordance with the Clean Development Mechanism (CDM) rules at no additional cost to investors.
RAM Active Investments
RAM Active Investments is a systematic asset manager with a long experience in creating value for its customers in any market condition. Research is at the heart of our disciplined approach to investment, which enables us to identify and continually exploit new market inefficiencies by adopting the latest innovative technologies.
Founded in 2007 by Thomas de Saint-Seine, Maxime Botti and Emmanuel Hauptmann, RAM Active Investments, an affiliate of Mediobanca Group since March 2018, operates independently worldwide with more than 40 employees and four offices in Geneva (headquarter), Zurich, Luxembourg and Milan. Asset under Management of USD 3,1 billion as of end of December 2019.
To find out more about RAM Active Investments visit the website ram-ai.com or follow us on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005314/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
